Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New treatment in sight for ovarian cancer

31.08.2009
In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

"Our research team has long hoped to be able to target radiotherapy in this way," says oncologist Håkan Andersson from Sahlgrenska University Hospital, who is leading the research alongside professor Ragnar Hultborn from the Sahlgrenska Academy and radiation physicist Lars Jacobsson.

"There is a good chance of this treatment working, as the study indicates that a sufficient amount of the active substance reaches the tumour cells in the abdominal cavity without any measurable side-effects."

The aim of this initial patient study, just published in the Journal of Nuclear Medicine, was to study the substance's distribution in the body and any side-effects in nine women with ovarian cancer.

The new treatment has been developed jointly over a number of years by researchers at the Sahlgrenska Academy and Sahlgrenska University Hospital. The treatment entails injecting the patient with a radioactive isotope bound to carrier molecules. This complex has the ability to bind to structures on the surface of tumour cells where the isotope emits alpha particles with such a short range that only the very nearest tumour cells' DNA is destroyed. The injection is administered straight into the abdominal cavity.

"We have previously seen that mice with ovarian cancer given this treatment are generally cured without serious side-effects, so we hope that this will become an established and effective treatment for women with metastatic ovarian cancer," says Ragnar Hultborn, professor of oncology at the University of Gothenburg's Sahlgrenska Academy. "But it will still be several years of development."

The research is being funded partly by the Swedish Research Council and the Swedish Cancer Society.

"In our next study, 80 women with ovarian cancer will receive this treatment as a supplement to their ordinary treatment so that we can scientifically test whether the effect is as good in real patients as the animal studies indicate," Håkan Andersson says.

OVARIAN CANCER
Most ovarian tumours are benign, especially in younger women, but more than 700 women in Sweden are diagnosed with ovarian cancer each year. It is only once a tumour has grown to a substantial size and begun to spread that it produces symptoms, such as a bloated abdomen and pain. This means that ovarian cancer is often detected too late for surgical treatment alone, and adjuvant chemotherapy is required. Even then, many patients do not survive, and so new treatments are needed.
For more information please contact:
Consultant oncologist Håkan Andersson, Sahlgrenska University Hospital, tel +46 31 342 7896, hakan.la.andersson@vgregion.se
Professor Ragnar Hultborn, Sahlgrenska Academy, Gothenburg University, ragnar.hultborn@oncology.gu.se
Journal: Journal of Nuclear Medicine
Title of article: Intraperitoneal Alpha-particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2 - A Phase I Study
Authors: Håkan Andersson, Elin Cederkrantz, Tom Bäck, Chaitanya Divgi, Jörgen Elgqvist, Jakob Himmelman, György Horvath, Lars Jacobsson, Holger Jensen, Sture Lindegren, Stig Palm, Ragnar Hultborn

Partners in clinical research The Sahlgrenska Academy is the University of Gothenburg's health sciences faculty, while Sahlgrenska University Hospital is one of northern Europe's largest hospitals. The two institutions have almost 300 different joint research projects under way. Their strongest research fields include obesity with cardiovascular research and diabetes, biomaterials, pharmacology, neuroscience, paediatrics, epidemiology, rheumatology and microbiology.

Helena Aaberg | idw
Further information:
http://www.sahlgrenska.gu.se
http://www.sahlgrenska.gu.se/aktuellt/nyheter/Nyheter+Detalj//Ny_behandling_mot_aggstockscancer_i_sikte.cid885984
http://www.gu.se/

More articles from Health and Medicine:

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

nachricht Stem cell transplants: activating signal paths may protect from graft-versus-host disease
20.04.2017 | Technische Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

DGIST develops 20 times faster biosensor

24.04.2017 | Physics and Astronomy

Nanoimprinted hyperlens array: Paving the way for practical super-resolution imaging

24.04.2017 | Materials Sciences

Atomic-level motion may drive bacteria's ability to evade immune system defenses

24.04.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>